Discovery of a potent EGFR and ALK dual mutation inhibitor containing N-(3-((4-((2-(cyclopropylsulfinyl)phenyl)amino)pyrimidin-2-yl)amino) phenyl)acrylamide scaffold.

Li, Wei; Yao, Han; Gu, Chenxi; Ren, Yuanyuan; Liu, Jiadai; An, Baijiao; Hu, Wenhao; Li, Xingshu; Chan, Albert S C

Li, Wei; Yao, Han; Gu, Chenxi; Ren, Yuanyuan; Liu, Jiadai; An, Baijiao; Hu, Wenhao; Li, Xingshu; Chan, Albert S C.

Afiliação

Li W; School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, PR China.
Yao H; School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, PR China.
Gu C; School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, PR China.
Ren Y; School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, PR China.
Liu J; School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, PR China.
An B; School of Pharmaceutical Sciences, Binzhou Medical University, Yantai, Shandong Province 264003, PR China.
Hu W; School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, PR China.
Li X; School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, PR China.
Chan ASC; School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, PR China.

Bioorg Chem ; 129: 106188, 2022 12.

Article em En | MEDLINE | ID: mdl-36220003

Assuntos

Antineoplásicos; Receptores ErbB; Animais; Camundongos; Camundongos Nus; Acrilamida/farmacologia; Proliferação de Células; Linhagem Celular Tumoral; Relação Estrutura-Atividade; Inibidores de Proteínas Quinases/farmacologia; Apoptose; Mutação; Antineoplásicos/farmacologia; Ensaios de Seleção de Medicamentos Antitumorais

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores ErbB / Antineoplásicos Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google